

## ENSEMBLE THERAPEUTICS TO PRESENT AT 2012 ACR ANNUAL MEETING

*Proof-Of-Concept Data of Systemic Administration of Orally Active Small Molecule Antagonists of Interleukin-17 Selected for Presentation*

CAMBRIDGE, MA – October 29, 2012 – Ensemble Therapeutics, a biotechnology company developing Ensemblins™, a novel class of small molecule therapeutics with the power of biologics, announced today that a poster presentation on its orally active small molecule antagonists of Interleukin-17 has been selected for presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting taking place November 9-14, 2012 in Washington, DC.

- (Abstract #1810): Tuesday, November 13, 2012, 9:00am-6:00pm, “Identification and Characterization of Synthetic Small Molecule Macrocyclic Antagonists of Human IL17A”, David Livingston, Ensemble Therapeutics, Cytokines, Mediators and Gene Regulation, Poster Hall (Hall B)

### **About Ensemblins**

Ensemblins™ are a new class of synthetic macrocycles developed by Ensemble using its proprietary chemistry platforms, including DNA-Programmed Chemistry. Macrocyclic rings are found in many natural product-based drugs and bestow favorable pharmaceutical properties and powerful protein surface binding properties upon such drugs. Thus, macrocycles are uniquely suited to address many protein targets that cannot be modulated effectively by traditional small molecule pharmaceutical compounds. Macrocycles have been challenging to synthesize in large numbers and this has constrained their wider use in the industry. By extending beyond the limits of traditional small molecule drug discovery, Ensemble’s platform provides unmatched capabilities to successfully and reliably generate millions of macrocyclic Ensemblins as drug candidates, larger than any collection previously synthesized in the pharmaceutical industry.

### **About Ensemble Therapeutics Corporation**

Based in Cambridge, MA, Ensemble Therapeutics is deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Ensemble is leveraging its macrocyclic drug discovery expertise to fuel its proprietary drug candidate pipeline while also pursuing collaborations with pharmaceutical partners. Ensemble has established high-value partnerships including alliances with Boehringer Ingelheim, Genentech, Bristol-Myers Squibb and Pfizer. Ensemble develops Ensemblins against pharmaceutical targets for which a strong therapeutic rationale exists but which have not been previously or optimally addressed with traditional small molecules. Although some of those targets might be addressed with biologics, many opportunities remain unexploited either because a small molecule oral medication is a preferred route of administration or because the target is inaccessible to biologics. Ensemble’s internal discovery and development efforts are focused on the key therapeutic areas of oncology and immuno-inflammatory diseases, with its lead program, a

small molecule antagonist of Interleukin-17, a cytokine implicated in multiple inflammatory and autoimmune diseases, poised to enter development with an orally active candidate in early 2013. For more information, visit: [www.ensembletx.com](http://www.ensembletx.com).

Media Contact:

Gina Nugent  
The Yates Network  
617-460-3579